Skin Cancer

Many participants in the mobile screening program have never previously seen a dermatologist.

New studies suggest tattoo pigments migrate to lymph nodes, complicate skin exams, and may raise lymphoma risk—what dermatologists now watch for.

The newly published tool, ODD-SPOT, offers a plain-language, photo-supported alternative to the ABCDE criteria, designed to capture the key warning signs of BCC, SCC, and melanoma in accessible terms.

At AAD 2026, Todd Schlesinger, MD, highlighted how staging frameworks and clinicopathologic features can inform treatment decisions in nonmelanoma skin cancer.

New sunscreen filters, AI tools, and immunotherapies are reshaping skin cancer prevention and treatment, improving precision and long-term survival.

During the late-breaking research session at the 2026 AAD Annual Meeting 2026, Mary Spellman, MD, shared successful news about intratumoral PH762 for cutaneous carcinomas.

Melanoma cases keep rising, but AI-aided screening, gene profiling, and newer immunotherapies boost early diagnosis and long-term survival, according to Darrell Rigel, MD, MS.

New case-control study data link tattoo exposure to a higher melanoma risk, prompting fresh scrutiny of ink chemicals and long-term skin safety.

Although the number of women leaders in Mohs surgery has increased, significant gender disparities remain in leadership roles, productivity metrics, and speaking opportunities.

Recent reviews highlight that melanoma risk associated with occupational UV exposure varies by tumor subtype, anatomical site, and individual susceptibility.

A multicenter trial in China shows ALA-PDT clears Bowen’s disease in 97% with low recurrence, minimal scarring, and high patient satisfaction.

A newly defined Nodularity Index, measuring tumor depth relative to width, independently predicted melanoma-specific survival.

Clearance rates increased between days 29 and 57, with the highest activity observed in the 200-μg treatment group.

A combined group of ophthalmology and dermatology specialists traveled to communities in Nepal to conduct consultations, procedures, and teaching sessions, and specifically in dermatology, skin malignancy removals, trainings on biologics and JAKs, and melanoma detection demonstrations.

Skin adverse events linked to immunotherapy may correlate with improved tumor response and survival, underlining their clinical significance.

CLEAR CSCC is evaluating whether low-dose intralesional cemiplimab is noninferior to primary surgery, potentially offering a tissue-sparing alternative to standard surgical management.

Brian Berman, MD, PhD, explains actinic keratosis-to-SCC risk and newer PDT/field therapies that improve clearance with less pain.

A Winter Clinical Miami poster highlights intralesional cemiplimab for early CSCC, showing rapid responses and positive safety versus surgery.

A JAMA Dermatology study found that US veterans with documented Agent Orange exposure had approximately 30% higher odds of developing acral melanoma compared with unexposed veterans.

At the 2026 South Beach Symposium, Joel Claveau, MD, emphasized that accurate early diagnosis and proper staging are the cornerstones of effective melanoma management.

Todd Schlesinger, MD, highlights data supporting red light–activated PDT with 10% ALA gel for superficial basal cell carcinoma, discussing structured treatment protocols and manageable tolerability.

The FDA has accepted Biofrontera’s supplemental new drug application seeking approval of Ameluz photodynamic therapy for superficial basal cell carcinoma (sBCC), with a decision expected by September 28, 2026.

Todd Schlesinger, MD, reviews emerging randomized trial data supporting red light–activated photodynamic therapy with 10% aminolevulinic acid gel and outlines key considerations for patient selection in superficial basal cell carcinoma (sBCC).

Todd Schlesinger, MD, discusses emerging evidence, clearance outcomes, and practical considerations for using red light–based photodynamic therapy as a nonsurgical option in select superficial basal cell carcinoma (BCC) cases.